Literature DB >> 23796928

Efficacy of Amphotericin B at Suboptimal Dose Combined with Voriconazole in a Murine Model of Aspergillus fumigatus Infection with Poor In Vivo Response to the Azole.

Marcelo Sandoval-Denis1, F Javier Pastor1, Javier Capilla1, Josep Guarro2.   

Abstract

The combination of amphotericin B at a suboptimal dose (0.3 mg/kg) with voriconazole has shown efficacy in prolonging survival and reducing tissue burden in a murine model of disseminated infection by an isolate of Aspergillus fumigatus that had showed a poor in vivo response to the azole. The efficacy of the combined treatment was higher than that obtained with amphotericin B at 0.8 mg/kg.
Copyright © 2013, American Society for Microbiology. All Rights Reserved.

Entities:  

Year:  2013        PMID： 23796928      PMCID： PMC3754337          DOI： 10.1128/AAC.00563-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.

Authors:  Susanne Perkhofer; Helene Lugger; Manfred P Dierich; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

3.  Combination antifungal therapy for invasive pulmonary aspergillosis in a heart transplant recipient.

Authors:  Andres Beiras-Fernandez; Amir K Bigdeli; Thomas Nickel; Sebastian Michel; Peter Ueberfuhr; Bruno Reichart; Ingo Kaczmarek
Journal:  Exp Clin Transplant       Date:  2011-08       Impact factor: 0.945

Review 4.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

5.  Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles.

Authors:  M Pfaller; L Boyken; R Hollis; J Kroeger; S Messer; S Tendolkar; D Diekema
Journal:  J Clin Microbiol       Date:  2010-12-01       Impact factor: 5.948

6.  Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry.

Authors:  William J Steinbach; Kieren A Marr; Elias J Anaissie; Nkechi Azie; Shun-Ping Quan; Herwig-Ulf Meier-Kriesche; Senu Apewokin; David L Horn
Journal:  J Infect       Date:  2012-08-13       Impact factor: 6.072

7.  Effect of grapefruit juice on serum voriconazole concentrations in the mouse.

Authors:  A M Sugar; X P Liu
Journal:  Med Mycol       Date:  2000-06       Impact factor: 4.076

8.  Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia.

Authors:  Isabelle Durand-Joly; Serge Alfandari; Zinnédine Benchikh; Marion Rodrigue; Ana Espinel-Ingroff; Benoit Catteau; Christophe Cordevant; Daniel Camus; Eduardo Dei-Cas; Francis Bauters; Laurence Delhaes; Stéphane De Botton
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

9.  In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus.

Authors:  Eric Dannaoui; Olivier Lortholary; Françoise Dromer
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

10.  Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus.

Authors:  Peter A Warn; Andrew Sharp; Juan Mosquera; Jochen Spickermann; Anne Schmitt-Hoffmann; Markus Heep; David W Denning
Journal:  J Antimicrob Chemother       Date:  2006-10-27       Impact factor: 5.758
View more
  4 in total

1.  In vitro combination of voriconazole and miltefosine against clinically relevant molds.

Authors:  S Imbert; M Palous; I Meyer; E Dannaoui; D Mazier; A Datry; A Fekkar
Journal:  Antimicrob Agents Chemother       Date:  2014-09-08       Impact factor: 5.191

2.  Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.

Authors:  Maria Siopi; Nikolaos Siafakas; Sophia Vourli; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

3.  Successful treatment of Paecilomyces variotii peritonitis in a liver transplant patient.

Authors:  Meltem Polat; Soner Sertan Kara; Anıl Tapısız; Zeliha Demirtaş; Sinan Sarı; Ayşe Kalkancı; Hasan Tezer; Buket Dalgıç
Journal:  Mycopathologia       Date:  2014-12-23       Impact factor: 2.574

4.  In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis.

Authors:  Adela Martin-Vicente; Javier Capilla; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2015-10-26       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.